The levels of SYT13 and CEA mRNAs in peritoneal lavages predict the peritoneal recurrence of gastric cancer.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ metabolism
Carcinoembryonic Antigen
/ genetics
Case-Control Studies
Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Peritoneal Lavage
Peritoneal Neoplasms
/ genetics
RNA, Messenger
/ metabolism
Retrospective Studies
Stomach Neoplasms
/ genetics
Survival Rate
Synaptotagmins
/ genetics
Young Adult
Biomarker
Carcinoembryonic antigen
Gastric cancer
Peritoneal metastasis
Synaptotagmin XIII
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
21
01
2019
accepted:
25
04
2019
pubmed:
6
5
2019
medline:
15
4
2020
entrez:
6
5
2019
Statut:
ppublish
Résumé
Although peritoneal lavage cytology often serves as a sensitive method to detect free cancer cells in the abdominal cavity, some patients experience peritoneal recurrence despite negative cytology. The aim of this study was to evaluate mRNAs in peritoneal lavage fluid as potential markers for predicting the peritoneal recurrence of gastric cancer (GC). Peritoneal lavage fluid samples were obtained during surgery conducted on 187 patients with GC and from 30 patients with non-malignant disease (controls). The mRNA levels of nine candidate markers were quantified, and analysis of a receiver-operating characteristic curve compared their accuracies. The cutoff was defined as the highest value of the controls. Synaptotagmin XIII (SYT13) and carcinoembryonic antigen (CEA) mRNA levels were analyzed further. SYT13 levels were significantly associated with shorter peritoneal recurrence-free survival (PRFS) and overall survival. Among patients with negative peritoneal lavage cytology, those positive for either SYT13 or CEA mRNA experienced significantly shorter peritoneal recurrence-free survival compared with those with negative fluid (hazards ratio [HR] 4.21, P = 0.0114; HR 3.53; P = 0.0426, respectively). Univariate analysis revealed that SYT13 and CEA mRNA levels were significant predictors of peritoneal recurrence. Positive levels of both SYT13 and CEA mRNA demonstrated the highest HR for peritoneal recurrence (HR 12.27, P = 0.0064). Multivariable analysis revealed that SYT13 positivity was a significant independent prognostic factor (HR 3.69; 95% confidence interval, 1.18-12.74; P = 0.0246). Combined measurement of SYT13 and CEA mRNA levels in peritoneal lavage fluid could serve as a promising approach to predict peritoneal recurrence of GC.
Sections du résumé
BACKGROUND
Although peritoneal lavage cytology often serves as a sensitive method to detect free cancer cells in the abdominal cavity, some patients experience peritoneal recurrence despite negative cytology. The aim of this study was to evaluate mRNAs in peritoneal lavage fluid as potential markers for predicting the peritoneal recurrence of gastric cancer (GC).
METHODS
Peritoneal lavage fluid samples were obtained during surgery conducted on 187 patients with GC and from 30 patients with non-malignant disease (controls). The mRNA levels of nine candidate markers were quantified, and analysis of a receiver-operating characteristic curve compared their accuracies. The cutoff was defined as the highest value of the controls.
RESULTS
Synaptotagmin XIII (SYT13) and carcinoembryonic antigen (CEA) mRNA levels were analyzed further. SYT13 levels were significantly associated with shorter peritoneal recurrence-free survival (PRFS) and overall survival. Among patients with negative peritoneal lavage cytology, those positive for either SYT13 or CEA mRNA experienced significantly shorter peritoneal recurrence-free survival compared with those with negative fluid (hazards ratio [HR] 4.21, P = 0.0114; HR 3.53; P = 0.0426, respectively). Univariate analysis revealed that SYT13 and CEA mRNA levels were significant predictors of peritoneal recurrence. Positive levels of both SYT13 and CEA mRNA demonstrated the highest HR for peritoneal recurrence (HR 12.27, P = 0.0064). Multivariable analysis revealed that SYT13 positivity was a significant independent prognostic factor (HR 3.69; 95% confidence interval, 1.18-12.74; P = 0.0246).
CONCLUSIONS
Combined measurement of SYT13 and CEA mRNA levels in peritoneal lavage fluid could serve as a promising approach to predict peritoneal recurrence of GC.
Identifiants
pubmed: 31055693
doi: 10.1007/s10120-019-00967-3
pii: 10.1007/s10120-019-00967-3
doi:
Substances chimiques
Biomarkers, Tumor
0
Carcinoembryonic Antigen
0
RNA, Messenger
0
SYT13 protein, human
0
Synaptotagmins
134193-27-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143-1152Références
Eur J Cell Biol. 2001 Jan;80(1):41-7
pubmed: 11211934
Sci Rep. 2015 Jul 29;5:12538
pubmed: 26220081
Gastric Cancer. 2017 Jan;20(1):1-19
pubmed: 27342689
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
Mol Cell Proteomics. 2014 Feb;13(2):397-406
pubmed: 24309898
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Ann Surg Oncol. 2007 May;14(5):1694-702
pubmed: 17294072
Am J Transl Res. 2018 Jan 15;10(1):292-303
pubmed: 29423014
Cancer Med. 2018 Oct;7(10):5194-5204
pubmed: 30259711
J Clin Oncol. 2018 Jul 1;36(19):1922-1929
pubmed: 29746229
World J Gastrointest Oncol. 2015 Nov 15;7(11):285-91
pubmed: 26600928
Gastric Cancer. 2005;8(3):142-8
pubmed: 16086116
J Exp Clin Cancer Res. 2014 Aug 06;33:66
pubmed: 25096402
World J Gastroenterol. 2016 Aug 14;22(30):6829-40
pubmed: 27570420
Medicine (Baltimore). 2014 Sep;93(11):e83
pubmed: 25192488
Anticancer Res. 2018 Mar;38(3):1255-1262
pubmed: 29491048
Int J Cancer. 2016 Feb 1;138(3):721-30
pubmed: 26270236
Am J Surg. 1999 Sep;178(3):256-62
pubmed: 10527450
J Surg Oncol. 2013 Mar;107(3):237-42
pubmed: 23042588
J Surg Oncol. 1999 Oct;72(2):60-4; discussion 64-5
pubmed: 10518099
Br J Cancer. 2007 Aug 20;97(4):550-6
pubmed: 17667927
Lancet Oncol. 2013 Nov;14(12):e535-47
pubmed: 24176572
J Clin Oncol. 2011 Nov 20;29(33):4387-93
pubmed: 22010012
Tumour Biol. 2014 Apr;35(4):3463-70
pubmed: 24282089
Biochem J. 2001 Mar 1;354(Pt 2):249-57
pubmed: 11171101
Ann Surg. 2002 Apr;235(4):499-506
pubmed: 11923605
Ann Surg. 2018 Mar;267(3):495-503
pubmed: 28026832
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Int J Cancer. 2000 Sep 20;89(5):411-7
pubmed: 11008202
Oncol Rep. 2007 Mar;17(3):667-72
pubmed: 17273749
PLoS One. 2016 Mar 17;11(3):e0151608
pubmed: 26986965
Br J Surg. 2018 Sep;105(10):1349-1358
pubmed: 29741294